Navigation Links
Combination of Key Nutrients Reduces Stress and Emotional Problems in Those with Attention Deficit Hyperactivity Disorder (ADHD) Research Shows

WICHITA, Kan., Feb. 11, 2013 /PRNewswire-USNewswire/ -- Attention deficit hyperactivity disorder (ADHD) affects approximately two million American children, and this condition has grown to become the most commonly diagnosed behavioral disorder of childhood. The cause of ADHD is generally acknowledged to be multifactorial, involving both biological and environmental influence.

Nutritional deficiencies, including deficiencies in fatty acids (EPA, DHA), the amino acid methionine, and the trace minerals zinc and selenium, have been shown to influence neuronal function and produce defects in neuronal plasticity, as well as impact behavior in children with attention deficit hyperactivity disorder. These nutritional disturbances or variations from reference values have been associated with behavior typical of ADHD.

The investigation was undertaken to determine the reference values of specific biochemical markers that have been associated with behavior typical of ADHD in a group of patients before and after metabolic correction.

The study was based on data extracted from the Riordan Clinic's patient history database covering a period of over ten years. Researchers performed laboratory tests in 116 patients 2.7-25 years old with a diagnosis of ADHD, and compared the distributions of fatty acids, essential metals, and the levels of metabolic stress factors with established reference ranges before and after interventions. In addition, the association between toxic metal concentrations and the levels of essential metals in these patients was analyzed.

Treatment of ADHD patients was performed according to principles of integrative management of this condition, and patients were treated by essential fatty acids, amino acids, minerals, probiotics and vitamins.

"According to our data, the metabolic correction of ADHD by supplementation can ameliorate ADHD symptoms. Eighty percent (80%) of children who were treated from several weeks to 1-2 years, demonstrated improvement of metabolic stress level, measured by pyrrole test. For these patients, the levels of EPA were increased and the omega-6/omega-3 ratio was improved," states Dr. Nina Mikirova , Director of Research at the Riordan Clinic.

Putting all data together, it was demonstrated that after consumption of a combination of fatty acids as well as magnesium and zinc, amino acids, vitamins and probiotics, most subjects had a considerable reduction in markers of metabolic stress and reported less emotional problems.

Further studies need to be conducted with integrative metabolic correction therapy to determine its value in the management of ADHD.

This research, conducted by Riordan Clinic scientists Mikirova NA, Rogers AM, Taylor PR, Hunninghake RE, in collaboration with scientists from the School of Public Health, Medical Sciences Campus of the University of Puerto Rico, Miranda-Massari JR, and Gonzalez MJ, has recently been published in the Journal of Functional Foods in Health and Disease as "Metabolic correction for attention deficit/hyperactivity disorder: A biochemical-physiological therapeutic approach."

The full text of the article can be found at To read this and other articles written by Riordan Clinic researchers, go to

Riordan Clinic ( is a progressive nutrition-based medical clinic and a 501c3 nonprofit organization established in 1975 in Wichita Kansas.  It is comprised of a CLIA Certified laboratory, Bio-Center Laboratory; an orthomolecular clinic specializing in the treatment of chronic disease; a library registered with the National Libraries of Medicine; and a research division specializing in the study of nutritional remedies, degenerative and chronic disease, and analytical method development.  For more information call Dr. Nina Mikirova 316-682-3100 or email:

SOURCE Riordan Clinic
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
2. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
3. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
4. New nano-material combinations produce leap in infrared technology
5. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
6. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
7. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
8. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
9. Vaccination reduces the risk of unvaccinated badger cubs testing tuberculosis positive
10. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
11. Computer vision reduces risk in clinical trials
Post Your Comments:
(Date:10/12/2015)... CITY , Oct. 12, 2015 /PRNewswire/ - Aeterna ... specialty biopharmaceutical company engaged in developing and commercializing novel ... the departure of Dennis Turpin , the Company,s ... decision to close its Quebec City ... Chairman, President and Chief Executive Officer of the Company ...
(Date:10/12/2015)... October 12, 2015 ... version for enriched online experience --> ... to print version for enriched online experience ... media alternative to print version for enriched online ... of scientific, technical and medical information products and services, ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a ... retinal diseases that can safely and chronically be administered as an eye drop, announced ... co-hosted by The Cleveland Clinic and taking place October 25th to October 28th at ...
(Date:10/10/2015)... Maryland , le 10 octobre 2015 Le ... a intégré dans le Registre du Congrès sa ... annuelle pour la sensibilisation autour du plasma (IPAW), ... est sponsorisée par la Plasma Protein Therapeutics ... vise à : , Sensibiliser l,opinion ...
Breaking Biology Technology:
(Date:9/29/2015)... -- iDAvatars is excited to be named one of the first ... official announcement was recently made at an invite-only IBM ... San Francisco , where iDAvatars presented a demo of ... "It is both an honor and a privilege to ... market the cognitive power of IBM Watson in our product, ...
(Date:9/28/2015)... , September 28, 2015 ... expected to reach USD 12.03 billion by 2020, growing ... Technological advancements such as Backside Illumination (BSI) technique to ... over the forecast period.      (Logo: ... of the chip to reduce loss and, thus, reduce ...
(Date:9/26/2015)... -- Results of a TactioRPM pilot project in a ... Stanford Medicine X Conference. In a presentation titled ... Devices and Pharmacogenomics", Roger Simard , Pharmacist ... senior patients equipped with connected health devices and ... TactioRPM remote patient monitoring platform were empowered to ...
Breaking Biology News(10 mins):